TuisCSJA • FRA
add
Csl ADR
Vorige sluiting
€22,80
Jaarwisseling
€20,60 - €43,40
Markkapitalisasie
70,96 mjd AUD
Gemiddelde volume
1,00
P/V-verhouding
-
Dividend-opbrengs
-
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 4,17 mjd | -1,78% |
Bedryfskoste | 912,50 m | -0,05% |
Netto inkomste | 200,50 m | -80,02% |
Netto winsgrens | 4,81 | -79,67% |
Wins per aandeel | — | — |
EBITDA | 1,56 mjd | -2,16% |
Effektiewe belastingkoers | 24,74% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 1,14 mjd | -24,87% |
Totale bates | 37,90 mjd | -1,42% |
Totale aanspreeklikheid | 17,44 mjd | -2,56% |
Totale ekwiteit | 20,46 mjd | — |
Uitstaande aandele | 482,13 m | — |
Prys om te bespreek | 0,59 | — |
Opbrengs op bates | 8,70% | — |
Opbrengs op kapitaal | 10,43% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 200,50 m | -80,02% |
Kontant van bedrywe | 651,00 m | 3,42% |
Kontant van beleggings | -326,00 m | -78,14% |
Kontant van finansiering | -821,50 m | -70,79% |
Netto kontantverandering | -506,00 m | -750,42% |
Beskikbare kontantvloei | 712,50 m | -9,08% |
Meer oor
CSL Limited is an Australian multinational specialty biotechnology company that researches, develops, manufactures, and markets products to treat and prevent serious human medical conditions. CSL's product areas include blood plasma derivatives, vaccines, antivenom, and cell culture reagents used in various medical and genetic research and manufacturing applications. The company was established in 1916 as Commonwealth Serum Laboratories and was wholly owned by the Australian federal government until its privatisation in 1994. Wikipedia
Gestig
1916
Hoofkwartier
Webwerf
Werknemers
29 904
